Skip Navigation


Rheumatology Advance Access originally published online on June 8, 2004
Rheumatology 2004 43(9):1067-1068; doi:10.1093/rheumatology/keh242
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/9/1067    most recent
keh242v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Elewaut, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elewaut, D.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 9 © British Society for Rheumatology 2004; all rights reserved

Editorial

Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis

D. Elewaut

D. Elewaut, Department of Rheumatology, University Hospital Ghent, De Pintelaan 185, 9000 Gent Belgium

E-mail: Dirk.Elewaut@Ugent.be

The first 150 words of the full text of this article appear below.

Since its original synthesis more than half a century ago [1], methotrexate (MTX) has become an established drug in several medical specialties. Developed as a specific antagonist of folic acid, this drug was shown to inhibit proliferation of malignant cells primarily by inhibiting de novo synthesis of purines and pyrimidines [2]. Hence its original use primarily as a chemotherapeutic agent, but later it was also evaluated for the treatment of rheumatoid arthritis (RA) because of its presumed antiproliferative activities [3]. For more than 15 yr now it has been an established DMARD with pronounced anti-inflammatory activity that goes beyond inhibition of folic acid metabolism [2, 4]. In fact, several studies have indicated that its anti-inflammatory effects may be due to other mechanisms, such as adenosine release, which can induce immunosuppression [5]. Although MTX is definitely one of the most . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. Williamson and K. Yein
Potential failure of contraceptive efficacy in a patient taking methotrexate
Rheumatology, November 1, 2005; 44(11): 1461 - 1462.
[Full Text] [PDF]